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Background:  The risk of antibody-mediated rejection (AMR) in heart transplant patients is increased in multiparous females due to sensitization 
at the birth of the baby. Sensitization can also occur due to blood transfusions, ventricular assist device placement, and previous organ 
transplantation. Recently, through several registries, it has been found that gender mismatch, female donor-to-male recipient (F/M) or male donor-
to-female recipient (M/F), has lower survival. The cause and mechanism of this finding has not been elucidated. Since gender mismatch may 
enhance an immune response, we choose to assess the risk for increased AMR.
Methods:  We assessed our gender matched and mismatched patients transplanted between 1994 and 2010 to assess the incidence of 1st-year 
AMR. These patients were divided into 4 groups based upon donor and recipient gender: M/M (N=773), F/F (N=155), M/F (N=161), and F/M 
(N=210). AMR diagnosis was defined as pathologic, histologic and immunopathologic findings. These patients were assessed for treated AMR and 
asymptomatic AMR. Patients were on triple-drug immunosuppression.
Results:  We found that the incidence of 1st-year treated AMR was significantly increased in the M/F group compared to the M/M group (11% 
vs. 5%, p=0.005), and F/F group (11% vs. 6%, p=0.046). Similarly, the M/F group was found to have significantly increased 1st-year asymptomatic 
AMR compared to the M/M group (6% vs. 2%, p=0.016), but not to the F/F group (6% vs. 3%, p=0.18). The F/M group was found to have similar 
incidences of 1st-year treated AMR and asymptomatic AMR compared to the gender matched groups. In the M/F and F/F groups, there was no 
difference in terms of the percentage of multiparous females (64% vs. 73%, p=0.11). 
Conclusions:  Heart transplant patients with M/F recipient gender mismatch on triple-drug immunosuppression have an increased incidence of 
1st-year antibody-mediated rejection compared to gender match patients. Although multiparous female recipients are known to have more AMR, the 
F/F gender match group had similar outcomes to those of the M/M gender match group. Future efforts to understand and attenuate the underlying 
mechanisms are essential.
